Cellectis (ALCLS) Shares Preclinical Data; Plans 2027 China IIT

Cellectis (Nasdaq: CLLS) presented preclinical data for its .HEAL-101 gene therapy, showing 70% in vivo editing of human APOC3 and 76% triglyceride reduction in mice. The company plans a Phase 1 trial in China, with preliminary data expected in 2027. Cellectis aims to develop a one-time treatment for severe hypertriglyceridemia.

Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.

Cellectis (CLLS) reported Q2 2026 cash, cash equivalents and fixed-term deposits of $169M as of June 30, 2026, versus $145M in Q2 2025, citing runway into Q4 2027. At EHA 2026, lasme-cel in BALLI-01 moved to pivotal Phase 2 after FDA RMAT (June 2026), with ORR 67% and CR 56% in Phase 1. Eti-cel in NATHALI-01 showed ORR 46% and CR 31%.

Cellectis said the FDA granted RMAT designation to lasme-cel, its CD22-targeting allogeneic CAR-T candidate, for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company cited Phase 1 BALLI-01 data for efficacy and a manageable safety profile. Final Phase 1 results are scheduled for presentation at EHA on June 13; BALLI-01 Phase 2 enrollment is open.

Lockheed Martin (LMT) stock rose 31.7% over the past year, outpacing the S&P 500. The company is expanding its missile production capacity, with the Missiles and Fire Control segment reporting a 24% increase in sales and profit in fiscal Q3 2026. Lockheed is investing $300 million to expand its Texas operation and has a record backlog of $292 billion, including a $58.6 billion PAC-3 interceptor deal.

Alibaba, Tencent, and ByteDance are negotiating long-term server memory supply deals with Samsung and SK Hynix to address AI-driven shortages, according to South Korean media. Contracts may extend up to 10 years, with demand for DDR and LPDDR memory. Daishin Securities expects this to push memory prices higher. SemiAnalysis reports China has 24 GW of AI data center capacity, with more under construction.